The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
 
Arjun Vasant Balar
Honoraria - Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Incyte; Pfizer
Research Funding - Asana Biosciences (Inst); Genentech (Inst)
 
Yohann Loriot
Consulting or Advisory Role - Astellas Medivation; Astellas Medivation (Inst); AstraZeneca; AstraZeneca (Inst); Janssen; Janssen (Inst); MSD; MSD (Inst); Roche; Roche (Inst); Sanofi; Sanofi (Inst); Seagen; Seagen (Inst)
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche; Seagen
 
Jose Luis Perez-Gracia
Consulting or Advisory Role - BMS Brazil; Roche
Speakers' Bureau - BMS Brazil; Roche
Research Funding - BMS Brazil; MSD; Roche
Travel, Accommodations, Expenses - BMS Brazil; Roche
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Foundation medicine; Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis
 
Beiying Ding
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Xiaodong Shen
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche